Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): William Gray Added: 10 months ago
Safety and effectiveness outcomes of a 3-in-1 carotid stent delivery system show no major strokes at 30-day and one-year follow ups and significantly low rates of clinically driven target lesion revascularisation at two years.Dr William Gray (Main Line Health, Pennsylvania, US) joins us to discuss the first European presentation of the two-year outcomes from PERFORMANCE II (NCT04201132; Contego… View more
Author(s): Tiziana Claudia Aranzulla Added: 6 months ago
ESC Congress 2025 - Evolocumab on top of lipid lowering therapy(LLT) reduced adverse vascular events at 12 months.Dr Tiziana Claudia Aranzulla (Mauriziano Umberto Hospital, Turin, IT) joins us to discuss findings from CARUSO (NCT04730973). The trial aimed to assess the efficacy of evolocumab with traditional LLT compared to traditional LTT alone in the stabilisation and regression of carotid… View more
Author(s): Samineh Sehatbakhsh Added: 6 months ago
Navigate the complex landscape of coronary interventions following transcatheter aortic valve replacement with Dr Samineh Sehatbakhsh, addressing critical access challenges in an era of expanding TAVR indications.This essential presentation, part of the Complex Cases track, examines the growing clinical significance of post-TAVR coronary access as procedures expand to younger, lower-risk patients… View more
Author(s): Giovanni Luigi Di Maria Added: 2 years ago
TCT 23 - We are joined by Dr Giovanni Luigi Di Maria (John Radcliffe Hospital, UK) to discuss the findings of the PICSO-AMI-I study (NCT04958421), sponsored by Miracor Medical. The PICSO-AMI-I study aimed to assess the safety and feasibility of pressure-controlled intermittent coronary sinus occlusion (PiCSO) in patients with ST-elevation myocardial infarction (MI), presenting with TIMI 0 or 1… View more
Author(s): Rasha Al-Lamee , Michael Foley Added: 1 year ago
ACC.24 — Investigators, Dr Rasha K Al-Lamee and Dr Michael Foley (Imperial College London, UK) joined us to discuss the ORBITA COSMIC trial (NCT04892537).This randomized, double-blinded, placebo-controlled trial investigated the effects of coronary sinus reducer (CSR) as compared to placebo on myocardial perfusion via MRI, exercise duration, and symptoms in patients with refractory angina and… View more
Author(s): Mads Brix Kronborg Added: 2 years ago
ESC 2023 — Dr Mads Brix Kronborg (Aarhus University Hospital, DE) joins us to discuss the findings from the DANPACE II Trial (NCT00236158). DANPACE II (The DANPACE Investigator Group) trial aimed to compare patients who were randomised in a 1:1 ratio to either a base rate of 60 beats per minute and rate-adaptive DDD (DDDR-60 Group) or a base rate of 40bpm and non-rate adaptive DDD (DDD-40… View more